Arif Hussain, MD: Targeted drugs for renal cell cancer
The disease category of renal cancer had few advances in chemotherapy for decades, but within the last five years, more than six drugs have been approved around the world to treat renal call cancer. Most recently, Votrient was approved for GlaxoSmithKline, adding to the list of Sutent, Nexavar, Avastin, Torisel, and more. Some of these drugs are very important to the revenue of the drug and biotech companies (e.g. ONXX, GSK, NVS, PFE, Roche).
To help understand where all of these drugs fit in with the treatment algorithms now, we interviewed Arif Hussain, MD of the University of Maryland, a renal cell cancer expert, to give an overview.
Oncology, Univ Maryland | apples49 | 
June 4, 2010 1:54 pm
No Comments
No comments yet.
Notice: comments_rss_link is deprecated since version 2.5! Use post_comments_feed_link() instead. in /data/30/1/121/80/1121895/user/1185656/htdocs/wordpress/wp-includes/functions.php on line 3406
RSS feed for comments on this post.
TrackBack URI
